产品分类导航
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism

Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism

更新时间:2025-06-20

立即询盘
收藏

产品详情

产品名称: Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
产品分类: 其他生物制剂
CAS号: 2023788-19-2
药典: 中国药典,企业标准
级别: injection
产品关键词: Dual-Action Agonist,Type 2 Diabetes Treatment,Weight Management,Once-Weekly Dosing,GIP/GLP-1 Receptor Activation
是否为生产商:
产品包装规格: 5mg/Ampoule 10mg/Ampoule 15mg/Ampoule 20mg/Ampoule 30mg/Ampoule 10Ampoules/Box
主要销售市场: 中国,北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

产品描述:






Mechanism of Action(作用机理)

Tirzepatide is a dual-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the actions of these two incretin hormones to enhance glucose homeostasis and appetite regulation:

  1. GIP Receptor Activation: Tirzepatide binds to the GIP receptor, stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels. It also promotes the clearance of dietary triglycerides and enhances lipid metabolism in adipose tissue.
  2. GLP-1 Receptor Activation: It activates the GLP-1 receptor, leading to additional insulin secretion, suppression of glucagon release, and slowing of gastric emptying. This interaction also reduces appetite and food intake by acting on the central nervous system.
  3. Synergistic Effects: By activating both receptors simultaneously, tirzepatide provides a more potent and comprehensive effect on glucose control and weight management compared to single-agonist therapies.

Applications(应用)

  1. Type 2 Diabetes Management: Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
  2. Weight Management: It is also indicated for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. Clinical trials have shown significant weight loss benefits.
  3. Other Potential Uses: Ongoing studies are exploring its potential in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and chronic kidney disease (CKD).

Dosage Instructions(用法用量)

  1. Initial Dose: The recommended starting dose is 2.5 mg once weekly.
  2. Titration: The dose can be increased to 5 mg, 7.5 mg, or 10 mg once weekly, depending on the patient's glycemic response and tolerability.
  3. Injection Instructions: Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.

Storage(保存)

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.


公司简介

上海浦津林州制药有限公司,始建于1974年,其前身是林州市市属工业企业--安阳市化学制药厂, 2015年9月更名为“上海浦津林州制药有限公司” 公司位于风景秀丽的太行山东麓,举世闻名的人工天河——红旗渠畔,交通便利,通讯发达。公司占地面积5.5万m2,建筑面积1.9万m2,其中仓储面积3000 m2;厂区绿化面积16000 m2,硬化面积8000 m2。现有职工300余人,固定资产总值6418万元,主导产品主要有葡萄糖酸钙、硫酸镁、维生素C、肌苷等35个注射液品种,在市场上深受广大客户青睐,市场前景广阔。公司为了进一步扩大生产规模,提升产品档次,提高市场占有率,先后投资3.6亿余元,进行技术改造,现在拥有12条符合国家GMP标准的小容量注射剂全自动生产线,并于2014年5月通过国家食品药品监督管理局GMP认证;新建车间年设计生产能力12亿支,可实现产值3亿多元,利税5000余万元。 近年来,公司创新意识不断增强,始终把“技术创新,科技兴厂”作为公司发展的宗旨,企业发展空间大、前景广阔,愿各界同仁、有识之士携手并进,共谋美好未来。

该公司其他产品

Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Mechanism of Action(作用机理)Tirzepatide is a dual-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the actions of these two incretin hormones to enhance glucose homeostasis and appetite regulation:GIP Receptor Activation: Tirzepatide binds to the GIP receptor, stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels. It also promotes the clearance of dietary triglycerides and enhances lipid metabolism in adipose tissue.GLP-1 Receptor Activation: It activates the GLP-1 receptor, leading to additional insulin secretion, suppression of glucagon release, and slowing of gastric emptying. This interaction also reduces appetite and food intake by acting on the central nervous system.Synergistic Effects: By activating both receptors simultaneously, tirzepatide provides a more potent and comprehensive effect on glucose control and weight management compared to single-agonist therapies.Applications(应用)Type 2 Diabetes Management: Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Weight Management: It is also indicated for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. Clinical trials have shown significant weight loss benefits.Other Potential Uses: Ongoing studies are exploring its potential in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and chronic kidney disease (CKD).Dosage Instructions(用法用量)Initial Dose: The recommended starting dose is 2.5 mg once weekly.Titration: The dose can be increased to 5 mg, 7.5 mg, or 10 mg once weekly, depending on the patient's glycemic response and tolerability.Injection Instructions: Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.Storage(保存)Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
Liraglutide for Weight Loss: Harnessing the Power of GLP-1 Receptor Agonism
Liraglutide for Weight Loss: Harnessing the Power of GLP-1 Receptor Agonism
Mechanism of Action(作用机理)Tirzepatide is a dual-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the actions of these two incretin hormones to enhance glucose homeostasis and appetite regulation:GIP Receptor Activation: Tirzepatide binds to the GIP receptor, stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels. It also promotes the clearance of dietary triglycerides and enhances lipid metabolism in adipose tissue.GLP-1 Receptor Activation: It activates the GLP-1 receptor, leading to additional insulin secretion, suppression of glucagon release, and slowing of gastric emptying. This interaction also reduces appetite and food intake by acting on the central nervous system.Synergistic Effects: By activating both receptors simultaneously, tirzepatide provides a more potent and comprehensive effect on glucose control and weight management compared to single-agonist therapies.Applications(应用)Type 2 Diabetes Management: Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Weight Management: It is also indicated for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. Clinical trials have shown significant weight loss benefits.Other Potential Uses: Ongoing studies are exploring its potential in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and chronic kidney disease (CKD).Dosage Instructions(用法用量)Initial Dose: The recommended starting dose is 2.5 mg once weekly.Titration: The dose can be increased to 5 mg, 7.5 mg, or 10 mg once weekly, depending on the patient's glycemic response and tolerability.Injection Instructions: Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.Storage(保存)Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Mechanism of Action(作用机理)Tirzepatide is a dual-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the actions of these two incretin hormones to enhance glucose homeostasis and appetite regulation:GIP Receptor Activation: Tirzepatide binds to the GIP receptor, stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels. It also promotes the clearance of dietary triglycerides and enhances lipid metabolism in adipose tissue.GLP-1 Receptor Activation: It activates the GLP-1 receptor, leading to additional insulin secretion, suppression of glucagon release, and slowing of gastric emptying. This interaction also reduces appetite and food intake by acting on the central nervous system.Synergistic Effects: By activating both receptors simultaneously, tirzepatide provides a more potent and comprehensive effect on glucose control and weight management compared to single-agonist therapies.Applications(应用)Type 2 Diabetes Management: Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Weight Management: It is also indicated for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. Clinical trials have shown significant weight loss benefits.Other Potential Uses: Ongoing studies are exploring its potential in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and chronic kidney disease (CKD).Dosage Instructions(用法用量)Initial Dose: The recommended starting dose is 2.5 mg once weekly.Titration: The dose can be increased to 5 mg, 7.5 mg, or 10 mg once weekly, depending on the patient's glycemic response and tolerability.Injection Instructions: Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.Storage(保存)Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
上海浦津林州制药有限公司
注册资本
联系人
查看联系方式
快速询盘
询盘主题
请输入询盘主题
询盘信息
请输入询盘信息
快速发送询盘
2006-2026 上海博华国际展览有限公司版权所有(保留一切权利) 沪ICP备05034851号-57